Litigation
Celgene Corporation v. Dr. Reddy's Laboratories, Ltd. et al.
judgment2:19-cv-15343
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2019-07-12
- Terminated
- 2022-02-23
Patents at issue (5)
Plaintiffs (1)
Summary
Celgene sued Dr. Reddy's in an ANDA/Hatch-Waxman action concerning pomalidomide (POMALYST®) patents, including U.S. Pat. Nos. 8,198,262; 8,735,428; 8,828,427; and 9,993,467. The narrative states that US3845770 does not appear to have been asserted in this case, despite its association with the patent-page litigation listing. Final judgment was entered on February 23, 2022.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).